Skip to main content

Table 5 Current ongoing early phase I/II trials with MET inhibitors

From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

MET Inhibitor

Drug name

Mechanism of action

Clinical trial (phase)

Study design

Disease

Bozitnib (APL-101)

c-MET receptor (HGFR) Inhibitor

NCT03175224 (1/2)

Monotherapy

c-MET altered solid tumors including NSCLC

Capmatinib (INC280)

MET Inhibition through HGFR binding

NCT04139317 (2)

Combination with Pembrolizumab

EGFR wild type and ALK negative NSCLC with high PDL1 expression

Capmatinib (INC280)

MET Inhibition through HGFR binding

NCT02414139 (2)

Monotherapy

EGFR wild type and ALK negative NSCLC with cMET alteration

Glumetinib

Small molecule MET kinase Inhibitor

NCT04338243 (1/2)

Monotherapy

T790M Mutation negative and Met amplified NSCLC

REGN5093

Bispecific antibody that Inhibits MET

NCT04077099 (1/2)

Monotherapy

MET altered NSCLC

Tepotinib

Selective MET inhibitor

NCT03940703 (2)

Combination with Osimertinib

MET amplified NSCLC with EGFR mutation

TFX-0022

MET, CSF1R, SRC kinase Inhibitor

NCT03993873 (1)

Monotherapy

NSCLC with MET alterations